Connect with us

Technology

China’s Next-Generation Exports: AI, Robotics and Innovative Medicines Emerge as New Growth Engines

Published

on

Robots, artificial intelligence and homegrown pharmaceuticals are overtaking electric vehicles, lithium batteries and solar cells as the fastest-growing categories in China’s foreign trade.

WASHINGTON, July 28, 2026 /PRNewswire-PRWeb/ — (This material is distributed by MediaLinks TV, LLC on behalf of CCTV. Additional information is available at the Department of Justice, Washington, D.C.)

Robots, artificial intelligence and homegrown pharmaceuticals are overtaking electric vehicles, lithium batteries and solar cells as the fastest-growing categories in China’s foreign trade.

China’s export portfolio is changing shape. A new generation of high-tech industries is now driving the country’s foreign trade growth, and it looks nothing like the last one. Artificial intelligence, robotics and innovative medicines, now being called the “new ‘new three,'” are gaining momentum as China’s latest export engines, taking over from the electric vehicles, lithium batteries and solar cells that powered the previous wave.

Panda Paws, a channel known for breaking down Chinese trends for Western viewers, released a short video this week walking audiences through the “new ‘new three'” in plain, digestible terms. Using quick on-screen facts, the video highlights the same throughline analysts are pointing to: China’s export edge is moving from manufacturing scale to research and innovation.

Analysts say this is more than a change in product mix. It reflects a real shift in the source of China’s export competitiveness, away from manufacturing scale and cost efficiency and toward research-intensive, technology-driven industries. The earlier “new three” rewarded companies that could produce at scale and keep costs down. The new sectors run on a different logic entirely: sustained R&D, continuous technological iteration, and value that comes from innovation rather than from cheaper inputs.

AI Extends Its Global Reach

China’s artificial intelligence industry is moving well past software sales alone. According to OpenRouter, a global AI model aggregation platform, Chinese large language models processed 36.11 trillion tokens in the third week of July 2026, a jump of more than 30% from the week before. That kept them in first place globally in weekly usage for a 12th straight week. Industry observers point out that AI exports now cover a much wider range of digital capabilities than that headline number suggests, including algorithm development, model deployment and AI agent applications, much of which never shows up in conventional trade statistics. Chinese AI technologies currently serve users in 141 countries and regions.

Robots Move From Showcase to Workplace

Chinese robotics is making the leap from demonstration technology to everyday industrial and service use. On factory floors, industrial robots can tighten a screw in five seconds, faster and more precisely than an experienced human worker. In the power sector, robots are now handling high-altitude transmission line repairs that used to require dangerous manual work. Service robots are getting smarter too. At exhibitions, they can understand spoken commands, navigate on their own and deliver items on request. In smart pharmacies, robots from different manufacturers are sharing the same AI platform to sort medicines together, which is paving the way for pharmacies that run unattended around the clock.

The trade numbers back this up. In the first half of 2026:

Exports of cleaning robots and intelligent bionic robots reached 18.09 billion yuan (about $2.7 billion)Industrial robot exports totaled 6.29 billion yuan, up 18.6% year on year, reaching 141 countries and regionsSurgical robot exports jumped 3.3 times over to 480 million yuan, and their export markets grew from 23 countries to 49

Innovative Medicines Gain International Recognition

China’s pharmaceutical innovation sector is reshaping the global competitive picture, too. Earlier this year, China became the first country to approve a selective orexin-2 receptor agonist for narcolepsy, a rare neurological disorder that causes excessive daytime sleepiness. Approval is now pending in the United States, Japan and the European Union.

In the first half of 2026, China’s National Medical Products Administration cleared 38 Class 1 innovative drugs. Eleven of those were globally novel medicines built on new targets and new mechanisms of action, all developed independently by Chinese companies. That single-half total matches the number of comparably novel drugs approved in all of 2025, a year in which domestic companies accounted for less than half.

Overseas licensing has picked up just as fast. Licensing deals reached roughly $110 billion in the first half of the year, equal to about 80% of the total for all of 2025. Those agreements cover 10 therapeutic areas, including oncology, metabolism, immunology and neuroscience, with buyers from 20 countries and regions, among them the United States, the United Kingdom, France and Italy. China now accounts for about 30% of the world’s innovative drugs currently in development, second only to the United States.

Coordinated Policy Support Behind the Shift

Peng Yazhe, a digital economy researcher at the China Galaxy Securities New Development Research Institute, told 21st Century Business Herald that the earlier “new three” were built on manufacturing fundamentals, where scale and cost control decided who won. The new sectors, he said, follow “a completely different industrial logic,” one built on knowledge and technology rather than production volume.

Zhu Keli, founder and dean of the China Institute of New Economy and chief expert on the intelligent economy, credited coordinated national policy for much of the momentum, pointing to the national “AI Plus” action plan along with dedicated support for robotics and the digital transformation of the pharmaceutical sector. In his view, all three industries have moved past simply exporting products. Now they’re exporting technology systems, clinical solutions and industrial operating models, which he called a clear sign of China’s growing strength in frontier technology.

From Manufacturing Powerhouse to Innovation Economy

Decades ago, Chinese exports of clothing, furniture and household appliances showed off the country’s manufacturing capacity. Today, AI, robotics and innovative medicines show something different: the ability to export not just products, but technology, know-how and solutions to problems that matter well beyond China’s borders. As the “new ‘new three'” pick up speed worldwide, they point to a bigger story already in motion, China’s shift from a manufacturing powerhouse to an innovation-driven economy.

Click here to watch – https://www.facebook.com/reel/1053967540948469

Media Contact

Han Peng, CGTN America, 1 2023931850, distribution@cgtnamerica.com

View original content:https://www.prweb.com/releases/chinas-next-generation-exports-ai-robotics-and-innovative-medicines-emerge-as-new-growth-engines-302837097.html

SOURCE CGTN America

Continue Reading

Technology

Horizon Petroleum Ltd. Announces Proposed $2,000,000 Secured Grid Promissory Note and Close of Its Shares for Debt Settlement

Published

on

By

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS./

CALGARY, AB, Oct. 22, 2026 /CNW/ — Horizon Petroleum Ltd. (the “Company” or “Horizon”) (TSXV: HPL) (FRA: HPM) (Tradegate: HPM) is pleased to announce that it intends to enter into a secured grid promissory note (the “Promissory Note”) with Wilco Investments Ltd., a company controlled by Trevor Williams who is a director of the Company, in the aggregate principal amount of up to CAD $2,000,000. 

The proceeds will be used to make deposits on three generators and on production facilities. The generators will have a combined generating capacity of 3 megawatts. This equipment is Horizon’s next investment in its gas to power strategy for its Lachowice natural gas development in Poland.

The Promissory Note will bear interest from the applicable issuance date at 12% per annum. The Promissory Note and accrued interest will be due on December 31, 2026 (the “Maturity Date”). The Maturity Date may be extended by mutual agreement between the parties. The Promissory Note may be prepaid in whole or in part at any time without penalty. The Promissory Note will be immediately due and payable upon completion by the Company of a financing of equity or debt of CAD $5,000,000 or more. The Promissory Note will be secured by Horizon’s electrical generating equipment in Poland.

The closing date is anticipated to be October 22, 2026.

Entering into the Promissory Note and the advance of funds thereunder are subject to the satisfaction of customary conditions, including the approval of the TSXV.

As Trevor Williams is a director of the Company, the Promissory Note will constitute a “related party transaction” pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Company intends to rely on the exemption from the formal valuation requirement pursuant to section 5.5(b) of MI 61-101 as the Company does not have securities listed on a specified market, and on the exemption from the minority shareholder approval requirement pursuant to section 5.7(1)(a) of MI 61-101 as the fair market value of the Promissory Note will not exceed 25% of the Company’s market capitalization.

In addition, the Company announces that it has completed an agreement to settle a total of CAD $524,000 of the Company’s debt (the “Debt”) with certain arm’s length and non-arm’s length parties (the “Shares for Debt Settlement”). The Debt payable to directors and officers of the Company who are Insiders (as such term is defined under the policies of the TSXV) is an aggregate of CAD $465,000 and the Company will settle the same by issuing to such parties 2,657,143 common shares at a deemed price of CAD $0.175 per common share. The Debt payable to arm’s length service providers is an aggregate of CAD $59,000 and the Company will settle the same by issuing to such parties 337,143 common shares at a deemed price of $0.175 per common share. 

The Shares for Debt Settlement was approved by disinterested shareholders at the shareholder meeting held on July 28, 2026. All securities issued in connection with the Shares for Debt Settlement will be subject to a statutory four-month hold period in accordance with applicable securities legislation. 

The Company has received final approval for the Shares for Debt Settlement from the TSXV. 

The Company relied on exemptions from the formal valuation and minority approval requirements of sections 5.5(b) and 5.7(1)(a) of MI 61-101 in respect of such insider participation in the Shares for Debt Settlement, based on a determination that fair market value of the participation by insiders did not exceed 25% of the market capitalization of Horizon, as determined in accordance with MI 61-101.

About Horizon Petroleum Ltd.

Calgary-based Horizon Petroleum Ltd. is focused on the appraisal and development of natural gas resources and clean energy opportunities in Europe, with the objective of contributing to European energy independence and security. Horizon is advancing its Polish natural gas assets through a technically focused, phased development strategy designed to unlock their commercial potential. Horizon’s management team and Board of Directors comprise oil and gas, business and finance professionals with significant international experience.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release contains “forward-looking statements” or “forward-looking information” (collectively referred to herein as “forward-looking statements”) within the meaning of applicable securities legislation. Such forward-looking statements include, without limitation, forecasts, estimates, expectations and objectives for future operations that are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Horizon. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur or be achieved. This press release contains forward-looking statements pertaining to, among other things, the Company entering into the Promissory Note, the terms of the Promissory Note, the anticipated closing date, reliance on exemptions under MI 61-101, the anticipated use of proceeds and the approval of the TSX-V.

Forward-looking information is based on current expectations, estimates and projections that involve a number of risks, which could cause actual results to vary and in some instances, to differ materially from those anticipated by Horizon and described in the forward-looking information contained in this press release.

Although Horizon believes that the material factors, expectations and assumptions expressed in such forward-looking statements are reasonable based on information available to it on the date such statements were made, no assurances can be given as to future results, levels of activity and achievements and such statements are not guarantees of future performance.

SOURCE Horizon Petroleum Ltd.

Continue Reading

Technology

BMO Announces Cash Distributions for Certain BMO ETFs and ETF Series of BMO Mutual Funds for October 2026

Published

on

By

TORONTO, Oct. 22, 2026 /CNW/ — BMO Asset Management Inc., as manager of the BMO ETFs, and BMO Investments Inc., as manager of the BMO Mutual Funds, today announced the October 2026 cash distributions for unitholders of BMO ETFs and unitholders of exchange-traded series of units of the BMO Mutual Funds (collectively, the “ETF Series”)¹ that distribute monthly, as set out in the table below. Unitholders of record of the BMO ETFs and the ETF Series of the BMO Mutual Funds at the close of business on October 29, 2026, will receive cash distributions payable on November 3, 2026.

The ex-dividend date and record date for all BMO ETFs and ETF Series of BMO Mutual Funds is October 29, 2026.

Details of the per unit cash distribution amount are as follows:

Monthly Distributions

 FUND NAME

FUND TICKER

CASH DISTRIBUTION PER UNIT $

BMO AAA CLO ETF

ZAAA

0.124

BMO AAA CLO ETF (Hedged Units)

ZAAA.F

0.117

BMO AAA CLO ETF (USD Units)*

ZAAA.U

0.120

BMO Aggregate Bond Index ETF

ZAG

0.038

BMO All-Equity ETF (Target Cash Flow Units)

ZEQT.T

0.100

BMO Asset-Backed Securities ETF

ZABS

0.123

BMO Asset-Backed Securities ETF (Hedged Units)

ZABS.F

0.119

BMO Asset-Backed Securities ETF (USD Units)*

ZABS.U

0.119

BMO Balanced ETF (Target Cash Flow Units)

ZBAL.T

0.049

BMO BBB CLO ETF

ZBBZ

0.163

BMO BBB CLO ETF (Hedged Units)

ZBBZ.F

0.155

BMO BBB CLO ETF (USD Units)*

ZBBZ.U

0.158

BMO Canadian Core Plus US Balanced ETF

ZBCB

0.060

BMO Canadian Dividend ETF

ZDV

0.075

BMO Canadian High Dividend Covered Call ETF

ZWC

0.120

BMO Canadian High Dividend Covered Call ETF (Target Cash Flow Units)

ZWC.T

0.333

BMO Canadian MBS Index ETF

ZMBS

0.082

BMO Core Bond Fund (ETF Series)

ZCRB

0.044

BMO Covered Call Canadian Banks ETF

ZWB

0.170

BMO Covered Call Canadian Banks ETF (Target Cash Flow Units)

ZWB.T

0.488

BMO Covered Call Canadian Banks ETF (USD Units)*

ZWB.U

0.210

BMO Covered Call Dow Jones Industrial Average Hedged to CAD ETF

ZWA

0.150

BMO Covered Call Dow Jones Industrial Average Hedged to CAD ETF (Target Cash Flow Units)

ZWA.T

0.413

BMO Covered Call Energy ETF

ZWEN

0.220

BMO Covered Call Energy ETF (Target Cash Flow Units)

ZWEN.T

0.488

BMO Covered Call Health Care ETF

ZWHC

0.160

BMO Covered Call Health Care ETF (Target Cash Flow Units)

ZWHC.T

0.413

BMO Covered Call Spread Gold Bullion ETF

ZWGD

0.170

BMO Covered Call Spread Gold Bullion ETF (Target Cash Flow Units)

ZWGD.T

0.333

BMO Covered Call Technology ETF

ZWT

0.350

BMO Covered Call Technology ETF (Target Cash Flow Units)

ZWT.T

0.413

BMO Covered Call US Banks ETF

ZWK

0.160

BMO Covered Call US Banks ETF (Target Cash Flow Units)

ZWK.T

0.450

BMO Covered Call Utilities ETF

ZWU

0.070

BMO Covered Call Utilities ETF (Target Cash Flow Units)

ZWU.T

0.625

BMO Credit Stress Opportunities ETF

ZCDX

0.000

BMO Credit Stress Opportunities ETF (USD Units)*

ZCDX.U

0.000

BMO Discount Bond Index ETF

ZDB

0.022

BMO Emerging Markets Bond Hedged to CAD Index ETF

ZEF

0.045

BMO Emerging Markets Bond Fund (ETF Series)

ZEMB

0.053

BMO Equal Weight Banks Index ETF

ZEB

0.150

BMO Equal Weight REITs Index ETF

ZRE

0.090

BMO Equal Weight Utilities Index ETF

ZUT

0.071

BMO Europe High Dividend Covered Call ETF

ZWP

0.110

BMO Europe High Dividend Covered Call ETF (Target Cash Flow Units)

ZWP.T

0.333

BMO Europe High Dividend Covered Call Hedged to CAD ETF

ZWE

0.120

BMO Europe High Dividend Covered Call Hedged to CAD ETF (Target Cash Flow Units)

ZWE.T

0.333

BMO Floating Rate High Yield ETF

ZFH

0.062

BMO Global Dividend Opportunities Fund (Active ETF Series)

ZGDV

0.034

BMO Global Enhanced Income Fund (ETF Series)

ZWQT

0.085

BMO Global High Dividend Covered Call ETF

ZWG

0.190

BMO Global High Dividend Covered Call ETF (Target Cash Flow Units)

ZWG.T

0.333

BMO Global Infrastructure Fund (Active ETF Series)

ZGIF

0.050

BMO Global REIT Fund (Active ETF Series)

ZGRT

0.055

BMO Government Bond Index ETF

ZGB

0.111

BMO Growth ETF (Target Cash Flow Units)

ZGRO.T

0.058

BMO High Yield US Corporate Bond Hedged to CAD Index ETF

ZHY

0.060

BMO High Yield US Corporate Bond Index ETF

ZJK

0.103

BMO High Yield US Corporate Bond Index ETF (USD Units)*

ZJK.U

0.098

BMO International Dividend ETF

ZDI

0.085

BMO International Dividend Hedged to CAD ETF

ZDH

0.085

BMO Laddered Preferred Share Index ETF

ZPR

0.060

BMO Laddered Preferred Share Index ETF (USD Units)*

ZPR.U

0.096

BMO Long Corporate Bond Index ETF

ZLC

0.053

BMO Long Federal Bond Index ETF

ZFL

0.027

BMO Long Provincial Bond Index ETF

ZPL

0.034

BMO Mid Corporate Bond Index ETF

ZCM

0.055

BMO Mid Federal Bond Index ETF

ZFM

0.035

BMO Mid Provincial Bond Index ETF

ZMP

0.043

BMO Mid-Term US IG Corporate Bond Hedged to CAD Index ETF

ZMU

0.049

BMO Mid-Term US IG Corporate Bond Index ETF

ZIC

0.071

BMO Mid-Term US IG Corporate Bond Index ETF (USD Units)*

ZIC.U

0.052

BMO Money Market Fund (ETF Series)

ZMMK

0.100

BMO Monthly Income ETF

ZMI

0.049

BMO Monthly Income ETF (USD Units)*

ZMI.U

0.026

BMO MSCI Canada IMI High Dividend Yield Index ETF

ZDIV

0.108

BMO Premium Yield ETF

ZPAY

0.200

BMO Premium Yield ETF (Hedged Units)

ZPAY.F

0.175

BMO Premium Yield ETF (USD Units)*

ZPAY.U

0.180

BMO Real Return Bond Index ETF

ZRR

0.060

BMO Short Corporate Bond Index ETF

ZCS

0.047

BMO Short Federal Bond Index ETF

ZFS

0.028

BMO Short Provincial Bond Index ETF

ZPS

0.024

BMO Short-Term US IG Corporate Bond Hedged to CAD Index ETF

ZSU

0.050

BMO Strategic Autocallable Income US Large Cap ETF

ZACU

0.305

BMO Strategic Autocallable Income US Large Cap ETF (Hedged Units)

ZACU.F

0.305

BMO Strategic Autocallable Income US Large Cap ETF (USD Units)*

ZACU.U

0.305

BMO Ultra Short-Term Bond ETF

ZST

0.110

BMO Ultra Short-Term US Bond ETF (USD Units)*

ZUS.U

0.178

BMO US Aggregate Bond Index ETF

ZUAG

0.075

BMO US Aggregate Bond Index ETF (Hedged Units)

ZUAG.F

0.069

BMO US Aggregate Bond Index ETF (USD Units)*

ZUAG.U

0.072

BMO US Dividend ETF

ZDY

0.080

BMO US Dividend ETF (USD Units)*

ZDY.U

0.060

BMO US Dividend Growth ETF

ZBDU

0.070

BMO US Dividend Growth ETF (Hedged Units)

ZBDU.F

0.070

BMO US Dividend Hedged to CAD ETF

ZUD

0.055

BMO US High Dividend Covered Call ETF

ZWH

0.140

BMO US High Dividend Covered Call ETF (Target Cash Flow Units)

ZWH.T

0.413

BMO US High Dividend Covered Call ETF (USD Units)*

ZWH.U

0.140

BMO US High Dividend Covered Call Hedged to CAD ETF

ZWS

0.120

BMO US High Dividend Covered Call Hedged to CAD ETF (Target Cash Flow Units)

ZWS.T

0.413

BMO US Preferred Share Hedged to CAD Index ETF

ZHP

0.080

BMO US Preferred Share Index ETF

ZUP

0.096

BMO US Preferred Share Index ETF (USD Units)*

ZUP.U

0.090

BMO US Put Write ETF

ZPW

0.125

BMO US Put Write ETF (USD Units)*

ZPW.U

0.125

BMO US Put Write Hedged to CAD ETF

ZPH

0.120

BMO USD Cash Management ETF

ZUCM

0.108

BMO USD Cash Management ETF (USD Units)*

ZUCM.U

0.104

*Cash distribution per unit ($) amounts are USD for ZAAA.U, ZABS.U, ZBBZ.U, ZWB.U, ZCDX.U, ZJK.U, ZPR.U, ZIC.U, ZMI.U, ZPAY.U, ZACU.U, ZUS.U, ZUAG.U, ZDY.U, ZWH.U, ZUP.U, ZPW.U, ZUCM.U.

1 BMO ETFs are managed by BMO Asset Management Inc., an investment fund manager, a portfolio manager, and a separate legal entity from Bank of Montreal. ETF Series of the BMO Mutual Funds are managed by BMO Investments Inc., an investment fund manager and a separate legal entity from Bank of Montreal

Any statement that necessarily depends on future events may be a forward-looking statement. Forward-looking statements are not guarantees of performance. They involve risks, uncertainties and assumptions. Although such statements are based on assumptions that are believed to be reasonable, there can be no assurance that actual results will not differ materially from expectations. Investors are cautioned not to rely unduly on any forward-looking statements. In connection with any forward-looking statements, investors should carefully consider the areas of risk described in the most recent prospectus.

This communication is for information purposes. The information contained herein is not, and should not be construed as, investment, tax or legal advice to any party. Investments should be evaluated relative to the individual’s investment objectives and professional advice should be obtained with respect to any circumstance.

The BMO ETFs or securities referred to herein (ZDIV) are not sponsored, endorsed or promoted by MSCI Inc. (MSCI), and MSCI bears no liability with respect to any such BMO ETFs or securities or any index on which such BMO ETFs or securities are based. The prospectus of the BMO ETFs contains a more detailed description of the limited relationship MSCI has with BMO Asset Management Inc. and any related BMO ETFs.

The Dow Jones Industrial Index is a product of S&P Dow Jones Indices LLC or its affiliates (SPDJI), and has been licensed for use by BMO Asset Management Inc. S&P®, S&P 500®, US 500, The 500, iBoxx®, iTraxx® and CDX® are trademarks of S&P Global, Inc. or its affiliates (S&P) and Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC (Dow Jones), and these trademarks have been licensed for use by SPDJI and sublicensed for certain purposes by BMO Asset Management Inc. The relevant BMO ETF (ZWA, ZWA.T) is not sponsored, endorsed, sold or promoted by SPDJI, Dow Jones, S&P, their respective affiliates, and none of such parties make any representation regarding the advisability of investing in such product(s), nor do they have any liability for any errors, omissions, or interruptions of the Index.

BLOOMBERG® and the Bloomberg Index are service marks of Bloomberg Finance L.P. and its affiliates, including Bloomberg Index Services Limited (BISL), the administrator of the index (collectively, Bloomberg) and have been licensed for use for certain purposes by BMO Asset Management Inc. Bloomberg is not affiliated with BMO Asset Management Inc., and Bloomberg does not approve, endorse, review, or recommend any BMO ETFs. Bloomberg does not guarantee the timeliness, accuracy or completeness of any data or information relating to the BMO ETFs.

BMO ETFs are not in any way sponsored, endorsed, sold or promoted by FTSE Global Debt Capital Markets Inc. (FGDCM), FTSE International Limited (FTSE), Frank Russell Company (Frank Russell), FTSE Fixed Income LLC (FTSE FI) or the London Stock Exchange Group companies (together with FGDCM, FTSE, Frank Russell and FTSE FI, the Licensor Parties). The Licensor Parties make no claim, prediction, warranty or representation whatsoever, expressly or impliedly, either as to (i) the results to be obtained from the use of the FTSE BMO ETF Indices, (ii) the figure at which any of the FTSE BMO ETF Indices stands at any particular time on any particular day or otherwise, or (iii) the suitability of an Underlying Index for the particular purpose to which it is being put in connection with the FTSE BMO ETFs. Each of the FTSE BMO ETF Indices is compiled and calculated by FGDCM of FTSE and all copyright in any of the FTSE BMO ETF Indices values and constituent lists vests in FGDCM or FTSE, respectively. The Licensor Parties shall not be liable (whether in negligence or otherwise) to any person for any error in any of the FTSE BMO ETF Indices and the Licensor Parties shall not be under any obligation to advise any person of any error therein. FTSE® is a trade mark of the London Stock Exchange Group companies and is used under licence.

Commissions, management fees and expenses all may be associated with investments in BMO ETFs and ETF Series units of the BMO Mutual Funds. Please read the ETF facts, fund facts or prospectus of the relevant BMO ETF or ETF Series of BMO Mutual Fund before investing. BMO ETFs and ETF Series units of the BMO Mutual Funds are not guaranteed, their values change frequently and past performance may not be repeated. BMO ETFs and ETF Series units may be bought and sold at market price on a stock exchange and brokerage commissions will reduce returns.

Distributions are not guaranteed and are subject to change and/or elimination depending on market conditions. The payment of distributions should not be confused with an investment fund’s performance, rate of return or yield. If distributions paid by an investment fund are greater than the performance of the fund, investors’ original investment will shrink. Distributions of net income and net taxable gains of a BMO ETF or an ETF Series will be included in the unitholder’s income for tax purposes in the year they are paid, whether or not such amounts are reinvested in additional units. A unitholder’s adjusted cost base (“ACB”) will be reduced by the amount of any return of capital (“ROC”). If a unitholder’s ACB goes below zero, such unitholder will have to pay capital gains tax on the amount below zero. Please refer to the summary of the principal income tax considerations set out in the prospectus for the relevant BMO ETF or ETF Series. Investors should also consult their own tax advisors about their individual circumstances.

The Target Cash Flow Units are subject to capital depletion risk. Target Cash Flow Units make monthly distributions of a fixed amount which may be comprised of, in whole or in part, a ROC. A ROC reduces the amount of an original investment and may result in the return to investors of the entire amount of an original investment.

The Target Cash Flow Units’ monthly distribution dollar amount is reset at the beginning of each calendar year. The dollar amount is a factor of the annualized distribution rate for the Target Cash Flow Units (which is the rate set out in the individual BMO ETF profiles in the applicable BMO ETF’s prospectus), the net asset value per unit of a series of a BMO ETF (NAVPS) as of the end of the previous calendar year, and the number of Target Cash Flow Units of the BMO ETF held at the time of the distribution. Although not expected, we may also adjust the monthly distribution during the year, if capital market conditions have significantly affected the ability of the BMO ETF to maintain the applicable distribution. If we make any such adjustment to the monthly distribution, we will issue a press release to communicate the change. The distribution rate applicable to the Target Cash Flow Units may be higher than the rate of return or the portfolio yield of the BMO ETF that offers such units. As a result, if you elect to receive some or all of the regular monthly distributions in cash, the value of your investment in the BMO ETF may decline over time.

For a summary of the risks of an investment in the BMO ETFs or ETF Series units of the BMO Mutual Funds, please see the specific risks set out in the relevant ETF facts, fund facts or prospectus. BMO ETFs and ETF Series units of the BMO Mutual Funds trade like stocks, fluctuate in market value and may trade at a discount to their net asset value, which may increase the risk of loss.

BMO ETFs are managed by BMO Asset Management Inc., an investment fund manager, a portfolio manager, and a separate legal entity from Bank of Montreal. BMO Mutual Funds are managed by BMO Investments Inc., an investment fund manager and a separate legal entity from Bank of Montreal.

BMO Global Asset Management is a brand name under which BMO Asset Management Inc. and BMO Investments Inc. operate.

“BMO (M-bar roundel symbol)” is a registered trademark of Bank of Montreal, used under licence.

Further information about BMO ETFs and ETF Series of the BMO Mutual Funds can be found at www.bmoetfs.com.

About BMO Financial Group 

BMO Financial Group is the eighth largest bank in North America by assets, with total assets of $1.5 trillion as of July 31, 2026. Serving clients for more than 200 years, BMO provides a broad range of personal and commercial banking, wealth management, global markets and investment banking products and services across Canada, the United States, and select markets globally. BMO is innovating for business value, by deploying and integrating human, digital and artificial intelligence to personalize client experiences, augment teams, and automate its business responsibly. Driven by its purpose, to Boldly Grow the Good in business and life, BMO is committed to driving positive change in the world, and making progress for a thriving economy, sustainable future, and stronger communities.

SOURCE BMO Financial Group

Continue Reading

Technology

ACL Digital Launches AgentixCare, a Human-in-the-Loop Agentic AI Platform for Healthcare Payers, Providers, and MedTech

Published

on

By

The AI-first platform applies agentic AI, generative AI, and predictive models across clinical care, revenue cycle management, and connected MedTech, with humans in control of every critical decision.

SAN JOSE, Calif., Oct. 22, 2026 /PRNewswire/ — ACL Digital, part of the ALTEN Group, today announced the launch of AgentixCare, a Human-in-the-Loop (HITL) Agentic AI platform for healthcare payers, providers, and MedTech organizations. A trusted AI-led Digital Enterprise & Systems Engineering Partner, ACL Digital drives innovation by designing and building intelligent systems across the full technology stack, from chip-to-cloud.

Traditional healthcare platforms record what happened but rarely act on it. Fragmented EHRs, manual prior authorizations, rising claim denials, and disconnected device data bury clinicians in documentation and leave revenue teams chasing paperwork. AgentixCare closes that gap, cutting costs by up to 30–50% while improving productivity, care quality, cash flow, and asset uptime, with HITL oversight at every decision point.

“Healthcare does not need another dashboard. It needs AI that does real clinical, financial, and operational work, safely. AgentixCare puts autonomous agents to work on the tasks that slow care down, from prior authorizations to denials to documentation, while keeping clinicians firmly in control. That is how our clients will move from AI pilots to measurable outcomes in weeks, not years,” said Ramandeep Singh, CEO of ACL Digital.

Unlike point solutions that bolt AI onto legacy workflows, the platform is built AI-first. Its agents assess data, gather clinical and policy evidence, assemble submissions, trace root causes, and recommend next-best actions.

End-to-End Coverage Across the Healthcare Value Chain

Clinical Care & Intelligence: EHR-ready AI notes, predictive early warnings, real-time clinical decision support (CDS), and formulary mapping.Agentic Revenue Cycle & Payer Operations: Electronic prior authorization and end-to-end claim and denial management, from scrubbing to recovery and reconciliation.Intelligent Connected MedTech: Predictive maintenance, performance analytics, a GenAI copilot for surgical robotics fleets, and infusion pump monitoring.AI-Governed Trust, Risk & Compliance: A compliance copilot for HIPAA and HITECH readiness.Future-Ready Interoperability: HL7 v2, FHIR R4, and SMART on FHIR connectors for leading enterprise and open-source EMRs.

The platform is designed to significantly reduce manual prior authorization work and administrative costs, speed up routine authorization decisions, cut claim denials and unplanned device downtime, catch more patient anomalies, and deliver faster answers through AI copilots and natural language processing.

“We engineered AgentixCare the way we build medical-grade systems: interoperable from day one, secure by design, and governed end to end. Every agent works on FHIR and HL7 data, every recommendation shows its evidence, and every action is approved and recorded. That combination of agentic AI and Human-in-the-Loop governance is what makes enterprise adoption fast and safe,” said Suresh Venkateswaran, Head – Digital Product Engineering Services at ACL Digital.

AgentixCare draws on ACL Digital’s decades of domain and product engineering experience with healthcare, life sciences, and medical device companies. Developed by the company’s Healthcare Center of Excellence, it combines first-hand knowledge of Clinical, Payer, and MedTech workflows with interoperability standards and responsible AI practices.

AgentixCare is available now for pilot programs. To request a demonstration, visit AgentixCare programs.

About ACL Digital

ACL Digital, part of the ALTEN Group, is a trusted AI-led Digital Enterprise & Systems Engineering Partner driving innovation by designing and building intelligent systems across the full technology stack from chip to cloud. By integrating AI and data-powered solutions, we help enterprises accelerate digital transformation, optimize operations, and achieve scalable business outcomes. Partner with us to turn complexity into clarity and shape the future of your organization. Learn more at www.acldigital.com.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/acl-digital-launches-agentixcare-a-human-in-the-loop-agentic-ai-platform-for-healthcare-payers-providers-and-medtech-302916672.html

SOURCE ACL Digital

Continue Reading

Trending